May 13, 2024
Data demonstrates the therapeutic potential of Factor H (CPV-104) as complement modulator and delivered preclinical proof-of-concept in C3G.
Oct 17, 2024
...is dedicated to pediatric case reports and Eleva’s Factor H (CPV-104) study program.
Oct 17, 2024
...is dedicated to pediatric case reports and Eleva’s Factor H (CPV-104) study program.
Jan 4, 2024
His appointment reflects the growing maturity of Eleva’s proprietary pipeline programs.
Next Page